Indoco Remedies has informed that it enclosed a Press release regarding receipt of tentative approval from USFDA, for the Company’s Abbreviated New Drug Application for Canagliflozin and Metformin Hydrochloride Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg, a generic equivalent of Invokamet® Tablets, 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg and 150 mg/1000 mg.
The above information is a part of company’s filings submitted to BSE.
